| Date | Title | Description |
| 07.12.2023 | Sera Prognostics Announces Primary Endpoint Criteria Met | Sera Prognostics Inc. today announced that the Data Safety Monitoring Board (DSMB) overseeing its pivotal Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study recommended stopping enr... |
| 01.02.2022 | Sera Prognostics Announces New Agreement With Multiplan, Expanding Patient Access to the PreTRM® Test | Salt Lake City – February 1, 2022 – Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today annou... |
| 02.12.2021 | Sera Prognostics Announces Pricing for PreTRM® Test, the Only Broadly Validated Blood Test to Assess Risk of Preterm Birth | New Assigned Rate Further Validates the Commercial Value of the PreTRM® Test
Salt Lake City – Dec 2, 2021 – Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innova... |
| 01.12.2021 | Sera Prognostics Announces Publication of Data Confirming the Performance of the Ibp4/shbg Biomarkers in Diverse Non-U.S. Populations | Results confirmed that a U.S. validated proteomics predictor could be applied in low and middle income countries to help address global preterm birth challenges
Salt Lake City, – December 1, 2021 – Sera Prognostics Inc., The Pregnancy Comp... |
| 30.11.2021 | Sera Prognostics Appoints Two New Board Members | Sera Prognostics Announces the Appointment of Zhenya Lindgardt to its Board of Directors
Ms. Lindgardt has served as Chief Executive Officer of The Commons Project Foundation (TCP), a global technology non-profit foundation focused on esta... |
| 04.11.2021 | Sera Prognostics Appoints Woodrow Myers, MD, MBA as Advisor Of Public And Political Affairs | Dr. Myers to support Sera’s commitment to reduce healthcare disparities among underserved communities
Salt Lake City, Nov. 4, 2021 (PR NEWSWIRE) —Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ: SERA), focused on improving maternal a... |
| 03.11.2021 | Sera Prognostics Announces Publication Of The Clinical Validation Of PreTRM® Threshold For Clinical Action | Publication illustrates the power of stratifying PreTRM® testing risk at or above a threshold of twice the average population risk of spontaneous preterm birth (sPTB).
Salt Lake City – November 3, 2021 – Sera Prognostics Inc., The Pregnanc... |
| 02.11.2021 | Sera Prognostics Announces Collaboration To Help Underserved Communities Make Informed Decisions About Prenatal Health | Partnership to include distribution of a children’s book with essential prenatal healthcare information and support in the form of pregnancy/NICU “care boxes”
Sera Prognostics Announces Collaboration To Help Underserved Communities Make In... |
| 30.09.2021 | Sera Prognostics appoints Dr. Michael R. Foley as Chief Medical Officer and Dr. Paul Kearney as Chief Data Officer | Sera Prognostics Appoints Dr. Michael R. Foley As Chief Medical Officer | Sera Prognostics
Dr. Michael R. Foley has been appointed to the position of Chief Medical Officer beginning in January 2022. Dr. Foley will lead all medical activiti... |
| 28.09.2021 | Sera Prognostics : Appoints Dr. Paul Kearney as Chief Data Officer | Brings extensive data science, bioinformatics and proteomics experience to foster further product innovation and informed healthcare insights into pregnancy
SALT LAKE CITY, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregn... |
| 20.09.2021 | Sera Prognostics to be Added to Russell 2000 Index | SALT LAKE CITY, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patien... |
| 15.09.2021 | Sera Prognostics : Appoints Dr. Michael R. Foley as Chief Medical Officer | SALT LAKE CITY, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patien... |
| 14.09.2021 | Sera Prognostics : Announces Publication of Health Economic Analysis Supporting PreTRM® Test-and-Treat Strategy to Improve Maternal and Infant Health | Publication illustrates clinical benefit of combining PreTRM® testing with evidence-based interventions to improve neonatal health and reduce total health costs
Positive impact on preterm births, neonatal intensive care admissions, overall ... |
| 14.09.2021 | Sera Prognostics Announces Publication Of Health Economic Analysis Supporting PreTRM® Test-and-treat Strategy To Improve Maternal And Infant Health | Publication illustrates clinical benefit of combining PreTRM® testing with evidence-based interventions to improve neonatal health and reduce total health costs
Positive impact on preterm births, neonatal intensive care admissions, overall... |
| 13.09.2021 | Sera Prognostics to Present at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit | SALT LAKE CITY, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patien... |
| 30.08.2021 | Sera Prognostics Reports Second Quarter 2021 Financial Results | SALT LAKE CITY, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patient... |
| 17.08.2021 | Sera Prognostics : rsquo; PreTRM® Test and Treat Strategy Benefits Demonstrated by Results of Prospective, Randomized Controlled Intervention Trial Evaluating Clinical Utility | Study demonstrates positive impact of the company’s PreTRM® test and treat strategy on improving neonatal healthcare
NICU and total hospital length-of-stay in preemies reduced by more than 70% Faster rate of discharge from the NICU for spon... |
| 17.08.2021 | Sera Prognostics’ PreTRM® Test and Treat Strategy Benefits Demonstrated by Results of Prospective, Randomized Controlled Intervention Trial Evaluating Clinical Utility | Study demonstrates positive impact of the company’s PreTRM® test and treat strategy on improving neonatal healthcare
NICU and total hospital length-of-stay in preemies reduced by more than 70%
Faster rate of discharge from the NICU for sp... |
| 11.08.2021 | Meet Josh Phillips and Darshana Zaveri, managing partners at Catalyst Health Ventures | CHV invests exclusively in seed, Series A and Series B companies in the medtech space
Venture capital used to be a cottage industry, with very few investing in tomorrow's products and services. Oh, how times have changed! While there are mo... |
| 14.07.2021 | Sera Prognostics Announces Pricing of Initial Public Offering | Salt Lake City – July 14, 2021 – Sera Prognostics, Inc., The Pregnancy Company® (“Sera”), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the... |
| 23.05.2021 | Sera Prognostics Completes $100M Series E Financing | Sera Prognostics, Inc., a Salt Lake City, UT-based pregnancy company, closed a $100m Series E financing.
Backers included Vivo Capital, aMoon Fund, Parian Global, and others, led by existing investors Anthem, Inc., and Blue Ox Healthcare Pa... |
| 19.05.2021 | Sera Prognostics announces study results and commercial partnership with Anthem | Sera announced results from a health and economic benefit evaluation of Sera’s PreTRM® test-and-treat strategy. The analysis was conducted in approximately 40,000 pregnant women who were members of the Anthem Health commercial insurance pla... |
| 29.04.2021 | Sera Prognostics Completes $100 Million Series E Financing Led by Blue Ox and Anthem | SALT LAKE CITY, April 28, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., The Pregnancy Company® (“Sera”), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, t... |
| 29.04.2021 | Daily funding roundup - April 29th, 2021 | Vectra AI raised $130M; Solidia Technologies landed $78M; Capsida Biotherapeutics secured $50M; Keep
Mosaic: Mosaic is a California based financing platform for U.S. residential solar and energy-efficient home improvement projects. Mosaic a... |
| 28.04.2021 | Vivo Invests in Sera Prognostics’ $100 Million Series E Financing | - |
| 05.02.2021 | PE Hub: Sera Prognostics' partnership with Anthem shows Blue Ox playbook in action | Charles Kennedy, CEO and managing partner at Blue Ox Healthcare Partners, told PE Hub that Sera Prognostics’ partnership with Anthem is the poster child of his firm’s investment strategy – underscoring a new way in which products are coming... |
| 05.02.2021 | Sera Prognostics partners with Anthem and Healthcore to improve outcomes for preterm babies | – Patient enrollment began in November for this rigorous prospective, randomized, controlled PRIME intervention trial to demonstrate the value of implementing the PreTRM® prevention strategy to improve neonatal outcomes and lower cost of ca... |
| 03.11.2020 | Dr. Charles Kennedy Presents at HLTH VRTL 2020 | See Charles’ Opening Keynote on Healthcare Investing & Deal Flow Outlook presented for the HLTH VRTL 2020 conference HERE.
Charles discusses the lessons learned from the COVID pandemic and the impact it will have on the healthcare indu... |
| 24.06.2020 | SERA PROGNOSTICS APPOINTS THOMAS J. GARITE, M.D. AS VICE PRESIDENT OF CLINICAL SCIENCES | June 24, 2020 –Salt Lake City Utah – Sera Prognostics, Inc., The Pregnancy Company™, focused on improving maternal and neonatal health through innovative precision biomarker approaches, today announced the appointment of Thomas J. Garite, M... |
| 02.04.2020 | SERA PROGNOSTICS APPOINTS JAY M. MOYES AS CHIEF FINANCIAL OFFICER | April 2, 2020 –Salt Lake City Utah –Sera Prognostics, Inc., The Pregnancy Company™, focused on improving maternal and neonatal health through innovative precision biomarker approaches, today announced the appointment of Jay M. Moyes as Chie... |
| 24.02.2020 | SERA PROGNOSTICS TO PRESENT AT THE 40TH ANNUAL COWEN HEALTH CARE CONFERENCE | February 24, 2020 — Sera Prognostics, Inc., the leading health diagnostics company dedicated to improving the lives of women and babies through individualized prenatal care, will be presenting at the upcoming Cowen 2020 Health Care Conferen... |
| 28.01.2020 | DATA CONFIRMING PERFORMANCE OF SERA PROGNOSTIC’S PRETRM® TEST PREDICTOR IN AN INDEPENDENT LARGE COHORT AND TESTING ENHANCEMENTS TO BE PRESENTED | SALT LAKE CITY, January 28, 2020 — Sera Prognostics, Inc., the leading women’s precision pregnancy company, today announced two podium presentations to take place at the Society for Maternal-Fetal Medicine’s 40th Annual Pregnancy Meeting in... |
| 13.01.2020 | Flannel Is the New Black at the 2020 J.P. Morgan Healthcare Conference | The J.P. Morgan Healthcare Conference has positioned itself as not only the first, but perhaps the most important event of the global health care conference calendar year. Motionette
On Monday, January 13, like a swarm of honey bees, thousa... |
| 09.01.2020 | SERA PROGNOSTICS ANNOUNCES COMPLETION OF IMPORTANT PREVENT PTB CLINICAL INTERVENTION STUDY USING THE PRETRM® TEST | Data quantifying the benefit of Sera’s PreTRM® strategy submitted for scientific review
SALT LAKE CITY – January 9, 2020 – Sera Prognostics, Inc., the leading health diagnostics company dedicated to improve the lives of women and babies th... |
| 18.11.2019 | NEW SCIENTIFIC PUBLICATION SHOWS SERA PROGNOSTICS IS LEADER IN ASSESSING PRETERM BIRTH RISK | Highlights the Proper Experimental Design and Reporting Required for Accurate Biomarker Prediction Performance
Sera Approach Exemplifies Best Practice for Building Population Screening Tests
SALT LAKE CITY – November 18, 2019 – Sera Progn... |
| 14.11.2019 | Sera Prognostics raises $36M to market its blood test that predicts risk of premature birth | Sera Prognostics, maker of a prenatal blood test to help predict the risk of premature births, has raised $36 million in venture capital funding to help commercialize its offering.
Sponsored by Agilent Technologies
How would you like to win... |
| 13.11.2019 | Sera Prognostics Raises $36M in Series D Financing | Sera Prognostics, a Salt Lake City, Utah-based health diagnostics company focused on women and babies through individualized prenatal care, raised $36m in Series D financing.
The round was led by Blue Ox Healthcare Partners alongside two st... |
| 13.11.2019 | SERA PROGNOSTICS RAISES $36 MILLION SERIES D FINANCING LED BY BLUE OX HEALTHCARE PARTNERS | Two Strategic Healthcare Companies Join Investment Round
Key Scientific Publication in Obstetrics & Gynecology Shows Sera is the Leading Authority in Assessing Preterm Birth Risk
SALT LAKE CITY – November 13, 2019 – Sera Prognostics, ... |
| 13.02.2019 | Sera Labs Lands $5M Funding from ToroVerde | LOS ANGELES--(BUSINESS WIRE)--Today Sera Labs Inc. announced an investment of $5 million from the Canadian based, Cannabis private equity fund, ToroVerde Inc.
Sera Labs is a leading online premier CBD brand already hailing unprecedented dig... |
| 13.02.2019 | Sera Labs Raises $5M in Funding | Sera Labs, Inc., a Los Angeles, CA-based online premier CBD brand, raised $5m in funding.
Canada-based cannabis private equity fund ToroVerde made the investment.
Founded and led by CEO Nancy Duitch, Sera Labs is an online premier CBD brand... |
| 03.03.2015 | Sera Prognostics Receives $10M Debt Facility from Square 1 Bank | Sera Prognostics, Inc, a Salt Lake City, Utah-based developer of women’s health diagnostics to improve the health of pregnant women and newborns, received a $10m debt facility from Square 1 Bank.
The company intends to use the proceeds to i... |
| 07.01.2015 | Sera Prognostics Closes $20 Million in Series B Financing | |
| 15.11.2011 | Sera Prognostics Raises $19.3M in Series A Funding | Sera Prognostics Inc., a Salt Lake City, UT–based company that develops tests to diagnose preterm birth and other pregnancy complications, has raised $19.3m in Series A funding.
The round was led by venture capital firms InterWest Partners,... |
| 15.11.2011 |
Domain Associates Boosts Biomarker Firm
| San Diego-based biotech venture investor Domain Associates is the lead investor on a biomarker firm, targeting the detection of preterm birth and other pregnancy complications. According to Sera Prognostics today, it has raised $19.3M in a ... |
